An interventional study of Recruitment maneuver and PEEP setting guided by EIT and PEEP setting according to routine practice in ARDS (Acute Respiratory Distress Syndrome), sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Acute Lung Injury with a site in China — 20 open to participants now, 20 under way, 1 of them phase 3. Acute Lung Injury · China.
Among the 59 studies in Acute Lung Injury with a site in China, this one is the 2nd largest by planned enrollment of the 31 interventional ones that give a count, is one of 8 that started in 2026, is one of 20 with no phase, reaches primary completion later than 18 of the 19 other live ones, and was the 52nd registered.
382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.
Browse Acute Lung Injury studies →20 of the 59 studies in Acute Lung Injury with a site in China are open now. Recruiting first, the newest first:
Shanghai Zhongshan Hospital · Sites in China
Ages 18–80
Southeast University, China · Sites in China, Korea, Republic of, Taiwan
Ages 19–90
Peking Union Medical College Hospital · Sites in China
Ages 18–75
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–80
Shanghai University of Traditional Chinese Medicine · Sites in China
Ages 18+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 45 Acute Lung Injury studies recruiting now, 25 (56%) set no upper age limit and 8 (18%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 7 · Phase 3 1 · Phase 4 1
First in 2006; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 574 is above the median of 60 across 227 interventional studies indexed under Acute Lung Injury.
Median enrollment 60 across the 31 interventional studies, 103 across the 28 observational. Of the 20 that completed or were terminated, 3 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 59 have an industry lead sponsor. The 10 most frequent:
Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Peking Union Medical College Hospital has 7 studies filed under Acute Lung Injury — fewer than ten, so there is no comparison to draw.
8 of the studies in Acute Lung Injury with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07342205Phase 3Shanghai University of Traditional Chinese MedicineA Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota Transplantation | 2027-06 |
| NCT07558538Shanghai Zhongshan HospitalA Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome | 2026-11-30 |
| NCT07307066Peking Union Medical College HospitalReal-Time Algorithm-Driven Ventilation Feedback to Improve Lung-Protective Ventilation in Patients With ARDS (REALVENT-study) | 2026-12-30 |
| NCT07477951Yongtao SunThe Impact of Automatic Lung Recruitment Postoperative Pulmonary Complications | 2026-12-31 |
| NCT06696638XiaoJing Zou,MDPhysiological Effects of Lung Impedance Tomography-Guided and Plat Pressure-Guided Phigh During APRV in Patients With ARDS | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 59 studies in Acute Lung Injury with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this multi-center randomized controlled clinical trial is to learn if an individualized, bedside electrical impedance tomography (EIT)-guided ventilation strategy (including EIT-guided prone positioning and PEEP titration) can improve outcomes compared with a conventional lung-protective ventilation strategy in adult patients with acute respiratory distress syndrome (ARDS).
The main questions it aims to answer are:
Does the individualized EIT-guided ventilation strategy reduce 28-day mortality in ARDS patients? Researchers will compare the EIT-guided intervention arm to a control arm receiving routine lung-protective ventilation (without bedside EIT guidance) to see if the EIT-guided approach lowers 28-day mortality and improves other clinical outcomes.
Adult ARDS patients who meet inclusion criteria will be assigned to EIT-guided group and control group through stratified randomization:
EIT-guided group: Undergo bedside EIT assessments using a China-manufactured EIT device to guide decisions about prone positioning and individualized PEEP titration (including a recruitment maneuver).
Control group: Receive PEEP setting per conventional PEEP-FiO₂ tables and prone positioning per standard clinical indications without EIT guidance.
Both groups: Receive standard supportive ICU care and routine outcome assessments at multiple time points.
Primary outcome: 28-day mortality. Other outcomes include ventilator-free days to day 28 and so on.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with ARDS receiving mechanical ventilation who meet the following diagnostic criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prone positioning and PEEP titration guided by China-manufactured EIT.
Other: Recruitment maneuver and PEEP setting guided by EIT · Behavioral: Prone positioning guided by EIT
PEEP set guided by conventional PEEP-FiO₂ table and prone positioning guided by routine clinical indications without EIT guidance.
Other: PEEP setting according to routine practice · Behavioral: Prone positioning according to routine practice
The EIT-guided group, will receive recruitment maneuver and PEEP titration guided by EIT to determine the optimal PEEP level.
The control group will receive routine ventilation strategy. Routine recruitment maneuver is not recommended but may be used as rescue therapy. PEEP is set using the conventional PEEP-FiO₂ table.
The EIT-guided group, will determine prone positioning therapy based on EIT.
The control group will determine prone positioning therapy based on routine practice.
28-day mortality
The survival status on the 28th day after randomization
Time frame: Day 28 after randomization
Ventilator-free days within 28 days after randomization
Ventilator-free days within 28 days after randomization
Time frame: within 28 days after randomization
Ventilator-free days within 14 days after randomization
Ventilator-free days within 14 days after randomization
Time frame: Within 14 days after randomization
Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 32 months after the start.
Of 51 non-industry interventional studies with no phase under Acute Lung Injury, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 34. This study's planned 32 months is above that.
Counting every sponsor, half of 52 studies reached it within 15 months; a quarter within 7 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking Union Medical College Hospital →